SCHEMBL21709267

SCHEMBL21709267

c1ccc(-c2ccc(-c3nc(N(c4ccc(-c5ccccc5)cc4)c4ccc(-c5ccccc5)cc4)c4ccccc4n3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.67
CYP2D6 P10635 8/20 0.67
CYP1A2 P05177 7/20 0.67
CYP2C9 P11712 6/20 0.67
CYP2C19 P33261 6/20 0.67
ALDH1A1 P00352 5/20 0.67
TSHR P16473 4/20 0.67
KDM4E B2RXH2 4/20 0.67
HPGD P15428 4/20 0.67
MAPT P10636 4/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
GLA P06280 3/20 0.67
LMNA P02545 3/20 0.67
HIF1A Q16665 2/20 0.67
RECQL P46063 1/20 0.67
PDE5A O76074 3/20 0.62
ACP1 P24666 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.60
TP53 P04637 4/20 0.56
ABCG2 Q9UNQ0 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16768509 0.86 PDE5A (0.57) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL24155355 0.84 CYP3A4 (0.52) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL17752655 0.83 KDM4E (0.45) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL26571591 0.82 MEN1 (0.67) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL21709426 0.82 MEN1 (0.67) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL21709456 0.82 CYP1A2 (0.47) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL21709455 0.80 CYP1A2 (0.48) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL16404334 0.79 CYP2D6 (0.87) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL1083866 0.79 CYP2D6 (0.81) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL24255829 0.78 L3MBTL1 (0.52) CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT CYP3A4 108/4885CYP2D6 24/4885CYP1A2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.